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Abstract
Background: Overexpression of mutant copper/zinc superoxide dismutase (SOD1) in rodents has provided useful
models for studying the pathogenesis of amyotrophic lateral sclerosis (ALS). Microglia have been shown to
contribute to ALS disease progression in these models, although the mechanism of this contribution remains to be
elucidated. Here, we present the first evidence of the effects of overexpression of mutant (TG G93A) and wild type
(TG WT) human SOD1 transgenes on a set of functional properties of microglia relevant to ALS progression,
including expression of integrin b-1, spreading and migration, phagocytosis of apoptotic neuronal cell debris, and
intracellular calcium changes in response to an inflammatory stimulus.
Results: TG SOD1 G93A but not TG SOD1 WT microglia had lower expression levels of the cell adhesion molecule
subunit integrin b-1 than their NTG control cells [NTG (G93A) and NTG (WT), respectively, 92.8 ± 2.8% on TG G93A,
92.0 ± 6.6% on TG WT, 100.0 ± 1.6% on NTG (G93A), and 100.0 ± 2.7% on NTG (WT) cells], resulting in decreased
spreading ability, with no effect on ability to migrate. Both TG G93A and TG WT microglia had reduced capacity to
phagocytose apoptotic neuronal cell debris (13.0 ± 1.3% for TG G93A, 16.5 ± 1.9% for TG WT, 28.6 ± 1.8% for NTG
(G93A), and 26.9 ± 2.8% for NTG (WT) cells). Extracellular stimulation of microglia with ATP resulted in smaller
increase in intracellular free calcium in TG G93A and TG WT microglia relative to NTG controls (0.28 ± 0.02 μM for
TG G93A, 0.24 ± 0.03 μM for TG WT, 0.39 ± 0.03 μM for NTG (G93A), and 0.37 ± 0.05 μM for NTG (WT) microglia).
Conclusions: These findings indicate that, under resting conditions, microglia from mutant SOD1 transgenic mice
have a reduced capacity to elicit physiological responses following tissue disturbances and that higher levels of
stimulatory signals, and/or prolonged stimulation may be necessary to initiate these responses. Overall, resting
mutant SOD1-overexpressing microglia may have reduced capacity to function as sensors of disturbed tissue/
cellular homeostasis in the CNS and thus have reduced neuroprotective function.
Background
Amyotrophic lateral sclerosis (ALS) is a progressive neu-
rodegenerative disorder characterized by selective
demise of upper motor neurons in the motor cortex and
lower motor neurons in the brainstem and spinal cord
[1,2]. Disease onset occurs in mid-life (50 to 60 years of
age) and is followed by a rapid (2 to 5 years), progres-
sive failure of the neuromuscular system and death.
Although the aetiology of ALS is yet to be fully eluci-
dated, several factors are likely to contribute to motor
neuron injury, including excitotoxic and oxidative motor
neuron damage, protein aggregation, impaired axonal
transport, mitochondrial dysfunction, and non-cell
autonomous damage mediated through glial cells -
astrocytes and microglia [3,4]. Most of the current
insights into disease pathogenesis come from studies on
animal models overexpressing mutant forms of Cu/Zn
superoxide dismutase 1 (SOD1) [5]. Autosomal domi-
nant inheritance of mutant SOD1 accounts for 20 per-
cent of familial ALS (FALS) cases, or 2 percent of all
ALS cases [6,7]. Overexpression of mutant forms of
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SOD1, including G93A, G37R and G85R mutant SOD1,
in animal models faithfully replicates pathological fea-
tures of the human disease [8-10]. Motor neurons
expressing mutant SOD1 can escape disease if sur-
rounded by a sufficient number of normal non-neuronal
cells [11]. Conversely, normal motor neurons sur-
rounded by mutant SOD1-containing non-neuronal cells
developed signs of cellular injury with the development
of ubiquitinated protein deposits [11]. Selectively redu-
cing the levels of mutant SOD1 in motor neurons
delayed early disease progression and extended lifespan
by a mean of 22 percent (64 days). In contrast, reducing
mutant SOD1 expression in microglia, the major
immune cell of the CNS with a monocyte/macrophage
phenotype, had no effect on onset and early disease but
showed a large protective effect in late stage disease and
ameliorated disease progression with a mean extension
of survival of 99 days [12]. Moreover, a significant slow-
ing of disease progression was observed in double trans-
genic G93A-SOD1/PU.1-/- mice when the mice received
wild type but not G93A-SOD1 bone marrow transplant
[13].
While the mechanisms of microglial disease propaga-
tion remain to be fully elucidated, studies indicate that
mutant SOD1-overexpressing microglia may acquire an
exaggerated inflammatory phenotype and neurotoxic
properties following sustained activation. Low levels of
inflammatory mediators are present in the cerebrospinal
fluid of ALS patients [14-16] and activated microglia are
detected in the CNS [17] and in the neighbourhood of
degenerating motor neurons in post-mortem studies of
the human disease [18]. SOD1 transgenic mouse and rat
models of ALS also display signs of an inflammatory
response in the CNS at all stages of the disease. Prior to
the clinical signs of disease onset, microglia are in an
early state of activation, and elevated levels of inflamma-
tory mediators such as interleukin (IL)-6 can be
detected [19,20]. With the onset of symptoms and
motor neuron cell death, fully activated (or reactive)
microglia are present in the CNS and microglial produc-
tion of the pro-inflammatory cytokine, tumour necrosis
factor (TNF)-a has been demonstrated [21-24]. Elevated
levels of TNF-a, monocyte chemoattractant protein
(MCP)-1, macrophage-colony stimulating factor (M-
CSF), interferon (IFN)-g and transforming growth factor
(TGF)-b [15,23,25,26] and an increase in cyclooxygenase
(COX)-2 activity and prostaglandin (PG) E2 levels
[14,15,23,25,27] have been shown in mutant SOD1
transgenic mouse tissues and microglial cells. Adminis-
tration of drugs such as minocycline, or inhibitors of
COX-2 and peroxisome proliferator-activated receptor
(PPAR), capable of reducing microglial activation,
delayed both disease onset and progression in mutant
SOD1 transgenic mice [28-31].
It is unknown whether microglia overexpressing the
wild type form of human SOD1 can acquire altered
functional properties. Overexpression of wild type SOD1
in animals did not reveal any overt pathology at four
months of age [32] except signs of deficiency of muscle
innervation and premature aging [33-36]. Thus, wild
type SOD1 could also contribute to neuronal pathogen-
esis. For example, autopsy material from familial as well
as sporadic ALS cases revealed Lewy body-like hyaline
inclusions within motor neurons that immunoreacted
with anti-SOD1 antibodies [37]. Overexpression of wild
type SOD1 in mutant SOD1 transgenic animals acceler-
ated the disease course and shortened the lifespan of
double transgenic animals [38]. Additionally, wild type
SOD1 acquired toxic properties similar to those of the
mutant forms of SOD1 following oxidative damage [39].
Therefore, it is possible that wild type SOD1-overexpres-
sing microglia may also have altered cellular properties
rendering the cells capable of propagating neuronal
damage.
In healthy animals, microglia perform a surveillance
function to maintain a physiologically healthy microen-
vironment [40]. They accomplish this by sampling the
surrounding tissue with numerous extruding and
retracting processes [41]. Alterations in the tissue
microenvironment induce microglial migration to the
site of damage, scavenging of extruded cellular or
plasma proteins and clearance of damaged cell compo-
nents through phagocytosis [41,42]. These dynamic
effector functions of microglia are dependent on the
presence of diverse surface receptors, including cytokine,
chemokine, immunoglobulin, and purinergic receptors
[43,44]. Efficient intracellular signalling, control of gene
expression, and tightly regulated function of the actin
cytoskeleton are also necessary for appropriate micro-
glial effector responses [45,46]. Interestingly, in vivo
recordings of labelled microglia from SOD1 G93A-over-
expressing mice revealed significantly increased micro-
glial response towards laser-induced single axon
transection at preclinical age (60 days) when compared
to that in control mice, and a subsequent reduction in
SOD1 G93A microglial response to the same injury with
disease progression (90 and 120 days) [47].
The purpose of the current study was to investigate
whether overexpression of the mutant SOD1 transgene
(TG G93A) or the wild type SOD1 transgene (TG WT)
in microglia could significantly alter their functional
properties, potentially contributing to neurodegeneration
and its propagation. Due to inherent differences between
the two colonies of transgenic mice that we observed in
our studies, we compared the differences between NTG
and TG cells within colonies, and not between colonies.
Specifically, we examined non-transgenic (NTG: NTG
(G93A) and NTG (WT)) and SOD1-overexpressing
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transgenic (TG G93A and TG WT) microglial surface
expression of integrin b-1 (a subunit of integrin cell
adhesion molecules), the ability of microglia to spread
on fibronectin-coated surfaces and to migrate over
astrocytic monolayers, the ability to phagocytose apopto-
tic neuronal cell debris, and intracellular calcium
changes in response to a pro-inflammatory stimulus,
extracellular ATP. Mutant SOD1 caused the most
marked changes in these functions but overexpression
of wild type SOD1 also produced significant changes.
Thus, it is essential to examine the effects of both
mutant and wild-type SOD1 when investigating the role
of microglial cells in ALS.
Results
Reduced expression of integrin b-1 by TG G93A microglia
Microglia were purified from mixed glial cultures of TG
WT, NTG (WT), TG G93A and NTG (G93A) mice.
Figure 1 presents immunostaining images of microglia
in mixed glial cultures and following purification. Mixed
glial cultures contained astrocytes and microglia (Figure
1A and 1B) but purification using a mild trypsinisation
method resulted in cultures consistent of cells positive
for the monocyte/macrophage marker F4/80 - microglia
(Figure 1C and 1D). To investigate if overexpression of
SOD1 in microglia could alter their interaction with the
extracellular matrix, cell surface expression of integrin
b-1 (the b1 subunit of integrins, a fibronectin receptor)
was measured in TG G93A and TG WT microglia and
compared to those in respective NTG cells. While TG
WT microglia had integrin b-1 levels comparable to
those in NTG (WT) cells (mean ± standard error of the
mean (SEM): 91.96 ± 6.6% on TG WT versus 100 ±
2.7% on NTG (WT) cells; Figure 1F), the expression of
integrin b-1 on TG G93A microglia was modestly but
significantly reduced when compared to NTG (G93A)
cells (mean ± SEM: 92.76 ± 2.8% on TG G93A versus
100 ± 1.6% on NTG (G93A) cells; p = 0.0493, Student’s
t test, Figure 1F). Additional file 1 presents the data of
Figure 1F in more detail.
Reduced spreading ability of TG G93A microglia
To investigate whether the reduced expression levels of
integrin b-1 by TG G93A microglia could impair inter-
actions of TG G93A microglia with the extracellular
matrix, the spreading of microglial cells on a fibronec-
tin-coated surface was examined. Figure 2 shows
representative images captured for a spreading micro-
glial cell (Figure 2A), and the same images modified
for cell surface area calculations (Figure 2B). Individual
microglia were analysed for the time taken to initiate
spreading after attaching to the fibronectin-coated sur-
face, and the subsequent speed of spreading, if initia-
tion was successful. The spreading profiles of TG WT
and NTG (WT) microglia were similar, and consisted
of comparable percentages of cells that spread immedi-
ately, after a delay of 100 s before initiating spreading,
or that were stationary, i.e. that failed to spread
(immediate: 72.2 ± 20.0% in TG WT versus 60.7 ±
13.0% in NTG (WT) cells; delayed: 11.1 ± 11.1% in TG
WT versus 6.3 ± 6.3% in NTG (WT) cells; stationary:
16.7 ± 9.6% in TG WT versus 33.0 ± 13.0% in NTG
(WT) cells, Figure 2C). In contrast, the spreading pro-
files of TG G93A and NTG (G93A) microglia differed
significantly. TG G93A microglia had a lower percen-
tage of immediate and a higher percentage of station-
ary cells when compared to NTG (G93A) microglia
(immediate: 43.7 ± 8.9% in TG G93A versus 73.5 ±
7.1% in NTG (G93A) cells; p = 0.0195, Student’s t test;
delayed: 18.3 ± 7.1% in TG G93A versus 11.5 ± 6.3%
in NTG (G93A) cells; stationary: 38.0 ± 9.5% in TG
G93A versus 12.8 ± 6.7% in NTG (G93A) cells; p =
0.0483, Student’s t test, Figure 2D).
Spreading and migration speeds are unaltered in TG
G93A microglia but are increased in TG WT cells
To further investigate if the reduced expression levels of
integrin b-1 by TG G93A microglia affected microglial
spreading and migration, the speeds of spreading and
migration were measured. While the ability to spread on
fibronectin-coated surface was impaired in the TG
G93A microglia (Figure 2D), the speed of spreading of
those TG G93A microglia that did spread was not dif-
ferent from that of spreading NTG (G93A) microglia
(8.6 ± 1.3 μm2/s for TG G93A versus 10 ± 1.3 μm2/s
for NTG (G93A) microglia, Figure 3A). Interestingly,
TG WT microglia that did spread had a greater speed
of spreading compared to NTG (WT), albeit not statisti-
cally significant (26.6 ± 4.3 μm2/s for TG WT versus
16.2 ± 3.3 μm2/s for NTG (WT) microglia; p = 0.0693,
Student’s t test, Figure 3A). To investigate if the spread-
ing impairment of TG G93A microglia could affect
migration, the speed of random migration of NTG
(G93A), TG G93A, NTG (WT) and TG WT microglia
on genotype-matched astrocytic monolayers was mea-
sured. TG G93A microglia had similar speed of migra-
tion as NTG (G93A) microglia (1.9 ± 0.3 μm/min for
TG G93A versus 1.6 ± 0.2 μm/min for NTG (G93A)
microglia). Again, TG WT cells showed increased speed
of migration when compared to NTG (WT) microglia
(1.9 ± 0.1 μm/min for TG WT versus 1.1 ± 0.1 μm/min
for NTG (WT) cells, p = 0.0004, Student’s t test, Figure
3B). Directional migration of NTG (G93A), TG G93A,
NTG (WT) and TG WT microglia towards the che-
moattractant MCP-1 was also investigated (Additional
file 2), without detectable differences in distance
migrated between the cells of the four genotypes (data
not shown).
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Reduced ability of TG WT and TG G93A microglia to
phagocytose apoptotic neuronal cell debris
To establish if the overexpression of SOD1 in microglia
altered the ability to phagocytose apoptotic cell debris,
the phagocytosis of apoptotic murine neuronal cell
(NSC34) debris by microglia was investigated. Microglial
cells, incubated with apoptotic NSC34 neuronal cell
debris, labelled with a membrane dye VybrantDiI, were
extensively washed to remove any unphagocytosed
material and immunostained with anti-integrin b-1 anti-
body to delineate the plasma membrane. Figure 4 pre-
sents the scoring scale used to score the level of
phagocytosis (Figure 4A) and representative immunos-
taining pictures of NTG (G93A) and TG G93A micro-
glia with the phagocytosed material (Figure 4B). The
percentage of microglia with medium (score 4) to high
(score 6) loads of phagocytic material were compared
between the four genotypes. TG G93A and TG WT
Figure 1 Microglial culture purity and reduced expression of integrin b-1 by TG G93A microglia. (A and B) Immunostaining of
representative mixed glial cultures used to purify microglia. The cultures were stained with anti-CD11b (green) and anti-GFAP (red) antibodies to
show microglia in green and astrocytes in red; nuclei were stained with Hoechst (blue). (C and D) Immunostaining with anti-F4/80 antibody of
purified resting (C) and activated with lipopolysaccharide (D) microglia. (E) Immunostaining of purified microglia with isotype control antibody
shows residual non-specific fluorescence with the isotype-matched antibody. Scale bar = 50 μm. (F) Cell surface integrin b-1 expression levels on
NTG (WT), TG WT, NTG (G93A) and TG G93A microglia. Data are presented as mean ± SEM; Student’s t test, * p = 0.0493 versus NTG (G93A) cells,
n = 14 TG G93A and nine NTG (G93A) mice from four litters, five TG WT and five NTG (WT) mice from two litters.
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microglia had a significantly lower percentage of micro-
glia scoring from 4 to 6 than the respective NTG cells
(13.0 ± 1.3% for TG G93A, 16.5 ± 1.9% for TG WT,
28.6 ± 1.8% for NTG (G93A) and 26.9 ± 2.8% for NTG
(WT) microglia, p = 0.0001, Student’s t test, Figure 4C).
Reduced intracellular calcium release in TG WT and TG
G93A microglia following extracellular ATP stimulation
To investigate whether the overexpression of SOD1 in
microglia affected intracellular calcium changes follow-
ing a pro-inflammatory stimulus, microglial intracellular
calcium concentration ([Ca2+]i) was measured before,
during, and after stimulation with 10 μM ATP. Stimula-
tion with ATP increased [Ca2+]i and withdrawal of ATP
resulted in a steady reduction of the [Ca2+]i to almost
baseline levels in microglia of all genotypes (Figure 5A
and 5B). Microglia of all four genotypes had comparable
baseline [Ca2+]i: 0.16 ± 0.01 μM for NTG (G93A), 0.14
± 0.01 μM for TG G93A, 0.12 ± 0.01 μM for NTG
(WT) and 0.13 ± 0.01 μM for TG WT. The first 10 s of
ATP stimulation resulted in an initial rapid increase of
[Ca2+]i in NTG microglia, followed by a steady reduc-
tion of [Ca2+]i during the remaining 50 s of ATP chal-
lenge. However, TG microglia displayed a different
pattern of [Ca2+]i changes; the initial peak in [Ca
2+]i was
absent in both TG G93A and TG WT microglia (Figure
5A and 5B). The first 10 s of ATP challenge only mod-
erately increased the [Ca2+]i in TG G93A and TG WT
microglia. This [Ca2+]i was maintained until ATP was
withdrawn. The area-under-the-curve (AUC) calcula-
tions quantified this pattern of [Ca2+]i changes, and
showed areas of 19.1 ± 1.8 μM*s for NTG (G93A) ver-
sus 14.4 ± 2.2 μM*s for TG G93A microglia, p = 0.0176,
Student’s t test, and 14.6 ± 1.5 μM*s for NTG (WT)
versus 11.9 ± 1.6 μM*s for TG WT cells, not signifi-
cantly different (Figure 5C). The highest value of [Ca2+]i
was significantly smaller in TG G93A and TG WT
microglia when compared to respective NTG cells and
was 0.28 ± 0.02 μM for TG G93A versus 0.39 ± 0.03
μM for NTG (G93A) cells, p = 0.003, Student’s t test,
and 0.24 ± 0.03 μM for TG WT versus 0.37 ± 0.05 μM
for NTG (WT) microglia, p = 0.0123, Student’s t test
(Figure 5D). Interestingly, stimulation of microglia with
a high concentration of ATP (1 mM for 1 min) reversed
this initial reduced response in [Ca2+]i changes, but only
in TG G93A microglia (Additional file 3).
Discussion
In the present study we compared an array of functional
properties of transgenic microglia overexpressing wild
type SOD1 or mutant SOD1 G93A to those of non-
transgenic control cells.
Integrin b-1 (fibronectin receptor b) is involved in
diverse cellular functions including cellular adhesion to
Figure 2 Reduced spreading ability of TG G93A microglia. (A)
Representative time-lapse frames of a microglial cell spreading on a
fibronectin-coated surface are shown as an example. Scale bar = 10
μm. (B) The same frames as in A modified for analysis of cell surface
area. The frames are matched with the time (in seconds (s)
indicated above arrow) that elapsed from the initiation of recording.
(C) Total spreading profile of NTG (WT) and TG WT microglia.
Microglia that initiated spreading within first 100 s of recording
were classified as “Spreading”. Microglia that initiated spreading
after the first 100 s of recording were classified as “Delayed”.
Microglia that did not spread during the entire recording time were
classified as “Stationary”. (D) Total spreading profile of NTG (G93A)
and TG G93A microglia. Data are mean ± SEM; Student’s t test, * p
= 0.0195 for Spreading and * p = 0.0483 for Stationary TG G93A
microglia versus respective NTG (G93A) cells, n = ten TG G93A mice
(36 cells) and nine NTG (G93A) mice (30 cells) from four litters, and
three TG WT mice (14 cells) and four NTG (WT) mice (14 cells) from
two litters.
Figure 3 Spreading and migration speeds of TG G93A and TG
WT microglia. (A) Speed of spreading (μm2/s) of NTG (WT), TG WT,
NTG (G93A) and TG G93A microglia, n = three TG WT mice (12
cells) and three NTG (WT) mice (ten cells) obtained from two litters,
and ten TG G93A mice (15 cells) and nine NTG (G93A) mice (20
cells) from four litters. (B) Speed of migration (μm/min) of NTG (WT),
TG WT, NTG (G93A) and TG G93A microglia on genotype-matched
astrocytic monolayers. Data are mean ± SEM; Student’s t test, *** p
= 0.0004 versus NTG (WT) microglia, n = three TG WT mice (ten
cells) and three NTG (WT) mice (ten cells) from two litters.
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extracellular matrix, focal adhesion, migration, actin
polymerisation/assembly, and regulation of the cell cycle
[48-50]. We observed only modestly reduced levels of
integrin b-1 on TG G93A microglia when compared to
the levels on NTG (G93A) cells. Also, the small sample
size of TG WT and NTG (WT) microglia may have pre-
vented the detection of differences in integrin b-1
expression levels in this cell population. Nonetheless,
reduced levels of integrin b-1 on TG G93A microglia
could lead to impaired adhesion, migration,
phagocytosis, and proliferation. To test whether the for-
mer three functions were altered in TG G93A microglia,
we examined microglial spreading on fibronectin-coated
surface, migration on genotype-matched astrocytic
monolayers, and phagocytosis of apoptotic neuronal cell
debris. We observed that although expression of integrin
b-1 was marginally reduced, and spreading ability
impaired, in TG G93A cells, these changes did not affect
the migration of TG G93A microglia, as the cells were
capable of migrating on genotype-matched astrocytes at
Figure 4 Reduced potential of TG WT and TG G93A microglia to phagocytose apoptotic neuronal cell debris. (A) Scoring scale (from 1
to 6) used to measure microglial phagocytic potential. Bar = 10 μm. (B) Representative images of NTG (G93A) and TG G93A microglia
immunostained with anti-integrin b-1 antibody (green) after incubation with VybrantDiI-labelled apoptotic neuronal cell debris (red-orange).
Scale bar = 50 μm. (C) Percentage of microglia with moderate to high phagocytic potential (scores 4 to 6). Data are mean ± SEM; Student’s t
test, *** p = 0.0001 versus respective NTG cells, n = six NTG (WT) and seven TG WT mice from three litters, and six NTG (G93A) and six TG G93A
mice from two litters, capturing 10-12 images per mouse.
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the same speed as NTG (G93A) cells. This observation
may indicate that the slightly reduced levels of integrin
b-1 expression on TG G93A microglia may have no sig-
nificant impact on the cellular spreading and migration,
or that additional receptor-ligand interactions compen-
sate for reduced integrin b-1 expression and impaired
spreading ability.
Our study also showed that overexpression of both
transgenes affected microglial phagocytosis of apoptotic
neuronal cell debris, an effect presumably unrelated to
the reduced integrin b-1 expression. Microglial uptake
of degenerating motor neuronal debris has been shown
in vivo after injection of toxin ricin into rat facial nerve
[51]. Microglia were the primary cells to clear neuronal
debris from degenerating neurons during development
or after neuronal injury in adult animals [52,53]. Effi-
cient clearance of SOD1 aggregates significantly
improved the disease course in ALS model mice [54].
Moreover, persistence of destroyed tissue debris was
capable of inducing and perpetuating CNS tissue inflam-
mation [55,56]. Thus, the impaired ability to phagocy-
tose apoptotic neuronal debris by TG WT, and more so
by TG G93A, microglia may contribute to disease
exacerbation.
Overexpression of SOD1 G93A as well as wild type
SOD1 altered the intracellular Ca2+ responses to extra-
cellular ATP stimulation. Cellular responses to extracel-
lular nucleotides are mediated via cell surface P2
purinoreceptors, now classified as metabotropic (P2Y)
receptors that mediate signalling through G-proteins,
and ionotropic (P2X) receptors that are directly coupled
to non-selective cationic receptors allowing for influx of
Ca2+ and Na+ and efflux of K+ [57]. Physiologically,
ATP-induced signalling attracts microglia to the site of
injury or cellular damage resulting in microglial activa-
tion [42,58]. Microglia express P2X4, P2X7, P2Y1, P2Y2,
P2Y6 and P2Y12 receptors [59-62], and their stimulation
initiates release of Ca2+ from intracellular stores. In
Figure 5 Reduced intracellular calcium release in TG WT and TG G93A microglia following extracellular ATP stimulation. (A) Intracellular
calcium concentration ([Ca2+]i, μM) changes in NTG (WT) and TG WT microglia following extracellular stimulation with 10 μM ATP for 1 min. The
period of ATP challenge is indicated with the bar. (B) Changes of [Ca2+]i in NTG (G93A) and TG G93A microglia following extracellular stimulation
with 10 μM ATP for 1 min. The period of ATP challenge is indicated with the bar. (C) Area-under-the-curve (AUC) values (μM*s) for NTG (WT), TG
WT, NTG (G93A) and TG G93A microglia. Data are mean ± SEM; Student’s t test, *p = 0.0176 versus NTG (G93A) microglia. (D) Highest [Ca2+]i
values (μM) recorded for NTG (WT), TG WT, NTG (G93A) and TG G93A microglia during 1 min challenge with 10 μM ATP. Data are mean ± SEM;
Student’s t test, *p = 0.0123 versus NTG (WT) and **p = 0.003 versus NTG (G93A) cells, n = three NTG (WT) mice (38 cells) and three TG WT mice
(39 cells) from two litters, three NTG (G93A) mice (50 cells) and three TG G93A mice (40 cells) from two litters.
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addition, stimulation through P2X receptors induces
non-selective ion exchange that may result is microglial
depolarisation [63]. Microglia from SOD1 G93A-overex-
pressing ALS mouse models were found to have an
increased expression of P2X4, P2X7 and P2Y6 receptors
and reduced ability to hydrolyse extracellular ATP [64].
Moreover, prolonged (3 to 24 hours) stimulation with
30 μM ATP induced higher levels of COX-2 expression
and elevated production of the pro-inflammatory cyto-
kine TNF-a in SOD1 G93A microglia compared to
NTG cells [64], demonstrating the exaggerated pro-
inflammatory phenotype of SOD1 G93A microglia.
However, during our experiments, short (1 min) stimu-
lation of microglia with 10 μM ATP demonstrated that
microglia overexpressing SOD1 G93A, or wild type
SOD1, had a reduced initial increase in intracellular Ca2
+ when compared to that in NTG cells, which suggests
an alteration of calcium release from the endoplasmic
reticulum. Thus, higher ATP levels, and/or prolonged
stimulation by the nucleotide, may be necessary in order
to elicit physiologically relevant responses from SOD1-
overexpressing microglia, although overstimulation leads
to exaggerated pro-inflammatory response from TG
G93A microglia (Reference [26] and Additional file 3).
To summarise, it is well characterized that in ALS ani-
mal models activated microglia contribute to neurode-
generation through production of neurotoxic
compounds following activation [13,64] and acquisition
of an exaggerated inflammatory phenotype [24,26].
Here, we show evidence that SOD1 transgenic microglia
have a reduced capacity to sense tissue disturbances
under resting conditions. The affected functions in rest-
ing SOD1 microglia are a reduced ability to phagocytose
apoptotic neuronal cell debris and an attenuated
response to extracellular ATP stimulation. We propose
that resting state microglia overexpressing SOD1 G93A,
or wild type SOD1, may contribute to disease pathogen-
esis through loss of efficient tissue-protective functions.
Also, caution must be used when ascribing alterations in
microglial behaviour to mutant SOD1 expression. Our
results indicate that wild-type SOD1 overexpression can
alter some properties of microglia and should be an
obligatory control in all experiments.
Conclusions
Microglia, the macrophages of the brain, are known to
play vital physiological roles in maintaining healthy CNS
tissue architecture and function. In ALS pathogenesis,
microglia contribute to disease progression through con-
tinuous activation and secretion of multiple pro-inflam-
matory and neurotoxic mediators. Here, we present the
novel findings that resting-state microglia overexpres-
sing wild type or mutant SOD1 transgenes have reduced
physiologic responses of apoptotic neuronal cell
clearance and release of Ca2+ from intracellular stores
upon ATP stimulation. Our findings indicate that trans-
genic SOD1 microglia may require higher concentra-
tions of stimulatory factors to elicit physiologically-
relevant functions, indicating reduced neuroprotective
behaviour of TG microglia.
Methods
Primary microglial culture preparation
All animals were handled in accordance with the guide-
lines of the Animals (Scientific Procedures) Act 1986.
Microglia were purified from mixed glial cultures as
described [26]. Briefly, the cortices of neonatal (1-2 days
old) human mutant SOD1 G93A transgenic mice,
human wild type SOD1 transgenic mice, and their non-
transgenic (NTG) littermates (NTG (G93A) and NTG
(WT), respectively) were stripped of meninges, washed
and triturated in Hank’s balanced salt solution with Ca2
+/Mg2+ containing 0.04% trypsin (Sigma), 0.1 mg/ml col-
lagenase (Calbiochem) and 0.05 mg/ml DNaseI (Sigma).
After trituration, the single cells were pelleted and pla-
ted in complete medium [Dulbecco’s modified Eagle’s
medium (DMEM; Cambrex Bioscience), 10% heat-inacti-
vated foetal calf serum (FCS; BioSera), 100 units/ml
penicillin and 100 mg/ml streptomycin (Gibco, Invitro-
gen)] at 60 000 cells/cm2 on poly-L-lysine (Sigma)
coated coverslips. For the purification of microglia, the
confluent cultures were subjected to shaking and mild
trypsinisation [13,65], which resulted in microglial cul-
tures of more than 90% purity.
Immunostaining
The cells were washed with phosphate-buffered saline
(PBS), fixed with 4% paraformaldehyde for 15 min and
permeabilised with 0.1% Triton X-100. Non-specific
binding was blocked with 5% FCS in PBS for 30 min.
The cells were incubated with rat anti-mouse CD11b
(Serotec), rat anti-mouse F4/80 (Serotec), or isotype
control (Serotec) primary antibodies in blocking buffer
at room temperature. After washing with PBS, cells
were incubated with the goat anti-rat-fluorescein iso-
thiocyanate (FITC) secondary antibody (Serotec) and,
where needed, with conjugated Cy3-anti-glial fibrillary
acidic protein (GFAP) antibody (Sigma) in blocking buf-
fer. After washing, the nuclei were stained with 0.2 μg/
ml Hoechst 33342 (Intergen) solution for 1 min and the
coverslips mounted on glass sides in mounting medium
(50% glycerol in PBS).
Measurement of integrin b-1 expression
Microglia isolated from mixed glial cultures were depos-
ited into U-bottomed 96-well plates at 20 000 cells/well,
washed in 200 μl fluorescence activated cell sorting
(FACS) buffer (PBS containing 0.2% w/v bovine serum
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albumin (BSA) and 0.1% w/v sodium azide) and incu-
bated with conjugated FITC-anti-mouse integrin b-1
(Biolegend) or FITC-isotype control antibody (Biole-
gend) in FACS buffer for 20 min on ice. Cell-associated
mean fluorescence intensity (MFI) was detected using a
BD FACSort (Becton Dickinson). The acquired geo-
metric mean fluorescence values of isotype antibody-
stained cells were subtracted from those of the FITC-
integrin b-1 stained cells. The resultant values were
then compared between respective NTG and TG cells,
after counting the mean MFI of NTG cells as 100%
(Additional file 1).
Spreading assay
Isolated microglia were added to an imaging chamber con-
taining a coverslip coated with 5 μg/ml of bovine fibronec-
tin (Calbiochem) as a substrate. Cells were visualized
under a × 40 oil immersion objective heated to 37°C with
an objective heater (Bioptechs, Intracel) and the spreading
of individual cells in phase contrast recorded by a time-
lapse automation, using Openlab 3.7.1 software. After the
cells touched the coated coverslip, the frames were cap-
tured every 5 s for a maximum of 15 min. The captured
frames were analysed with ImageJ plugins to obtain cell
surface area values for every frame. The cells were classi-
fied as “spreading” if they initiated cell surface area expan-
sion (spreading) within first 100 s of recording. The cells
were classified as “delayed” if they initiated cell surface
area expansion after the first 100 s of recording. The cells
were classified as “stationary” if they did not initiate cell
surface area increase during the entire recording time. For
every spreading cell, the cell surface area values of the
expanding (spreading) phase were plotted against the time
taken to reach those values, and the speed of spreading
was deduced from this relationship using GraphPad Prism
5.0 linear regression analysis.
Migration assay
Mixed glial cultures in T25 flasks (Croning) were placed in
a microscope chamber equilibrated to 37°C, 5% CO2,
(LEICA Microsystems AF6000LX microscope with envir-
onmental control) for time-lapse recordings. A × 10 objec-
tive field of cells was captured every 3 min for 15 h. Using
phase contrast microscopy, small phase-bright amoeboid
and ramified microglia were easily visible on top of the lar-
ger astrocytes that formed a confluent monolayer. The
captured frames were loaded into ImageJ software as one
stack, and microglia were chosen at random from each
field of view and analysed for the distance migrated.
Phagocytosis of neuronal cell debris
NSC34 cells (a murine motor neuronal cell line [66])
were labelled with a membrane dye [1, 1’-dioctadecyl-
3,3,3’,3’-tetramethylindocarboxyanine perchlorate
(VybrantDiI) with an emission wavelength in red-orange
spectrum (Invitrogen)] according to the manufacturer’s
protocol. The cells were then incubated for 48 h in
serum free DMEM to induce apoptosis through oxida-
tive stress [67], at which point cell death had occurred
in 90% of cells. The labelled NSC34 cell debris was col-
lected and frozen at -80°C. Microglial cells plated on
poly-L-lysine (Sigma) -coated 13 mm coverslips were
incubated with 500 μl of labelled NSC34 cell debris for
21 h at 37°C. Microglia were extensively washed with
PBS to remove any unphagocytosed debris, and immu-
nostained with conjugated FITC-anti-mouse integrin b-1
(Biolegend) antibody. Using fluorescence microscopy, an
operator blinded to the genotypes of microglial cells
scored the cells according to the uptake of VybrantDiI-
labelled material on a scale from 1 to 6 (Figure 4A).
Measurement of intracellular calcium concentration
The measurements of microglial intracellular free cal-
cium were carried out according to a previously pub-
lished method [68,69]. The cells were pre-incubated
with the membrane-permeable ester form of the high-
affinity ratiometric calcium dye Fura-2 AM (10 μM) for
15 min and allowed to de-esterify for 30 min at room
temperature (25°C). The cells were placed in a recording
chamber (3 ml), which was continuously perfused (10
ml/min) with a standard extracellular solution contain-
ing: HEPES 11.6 mM, Na+129.1 mM, Cl- 143.8 mM, K+
5.9 mM, Mg2+ 1.2 mM, Ca2+ 3.2 mM, and glucose 10.0
mM, at pH = 7.3. Fluorescent images were obtained
using × 40 objective on an Axiovert 200 microscope
(Carl Zeiss) fitted with a C9100 electron multiplier CCD
camera (Hamamatsu Photonics) at 345/380 nm excita-
tion (Polychrome IV, Till Photonics) and 510 nm emis-
sion filters. Devices and shutters were controlled by
Openlab 3.7.1 software, which provided image acquisi-
tion and continuous online Ca2+ concentration calcula-
tion by custom scripting at 1/s. The regions of interest
were defined over perinuclear/cytoplasmic regions of
microglia and changes in fluorescence ratios (345/380)
recorded at rest and during stimulation with specified
concentrations of ATP, which was applied with a cus-
tom-made solution applicator with a solution exchange
time of ~100 ms in the area of view. Background fluor-
escence subtraction was used and calcium concentration
calculated according to Grynkiewicz [70].
Statistical analysis
Due to inherent differences between the two transgenic
colonies of mice (transgenic SOD1 G93A and transgenic
SOD1 wild type) that we observed in our past experi-
ments, we limited our statistical comparisons to mea-
sure differences between NTG and TG cells within
colonies, and not between colonies. Data were analysed
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using GraphPad Prism 5.0 software. All data that fitted a
normal distribution were analysed using Student’s t test.
Data that did not fit a normal distribution were trans-
formed using Y = Log(Y) transformation.
Additional material
Additional file 1: Calculation of percent expression of integrin b-1
on primary microglia. (A) A representative example of flow cytometry
histograms for NTG (G93A) and TG G93A microglia with FITC-isotype
antibody or FITC-anti-integrin b-1 antibody is presented. Each histogram
contains data on the geometric mean fluorescence (Gm), coefficient of
variance (CV), marker position (0-430), number and percentage of cells
under the marker. (B) An overlay of histograms from another
independent experiment represents the FITC signal distribution for FITC-
isotype antibody stained TG G93A microglia (filled curve), FITC-anti-
integrin b-1 antibody stained TG G93A microglia (curve with dashed line)
and FITC-anti-integrin b-1 antibody stained NTG (G93A) microglia (curve
with solid line). The horizontal axis in (A) and (B), FL-1-H, is the detected
signal intensity of FITC on a logarithmic scale. An example of percentage
expression calculation is given below: 1. Under the marker M1 over 95%
of the cells are detected, with the Gm for NTG (G93A) microglia of 11.11
with specific antibody, and 4.54 with isotype antibody. 2. For these NTG
(G93A) microglia the integrin b-1 expression is 11.11 - 4.54 = 6.57, and
for TG G93A cells the integrin b-1 expression is 10.62 - 4.93 = 5.69.
These expression values are then converted to values on a linear scale.
The values for NTG (G93A) are set as 100% expression. The values from
TG (G93A) then converted to percent expression with respect to 100% of
NTG (G93A) cells.
Additional file 2: Migration of TG WT and TG G93A microglia
towards the chemoattractant MCP-1: (A) A representative image of
microglial cells on fibronectin-coated coverglass overlaying a Dunn
migration chamber with cells facing the chamber. The image was taken
on the LEICA Microsystems AF6000LX microscope on a x10 objective,
with environmental control to maintain the slide at 37°C. To record
migration, images were taken every 3 minutes for 1 hour using Leica
software. At the top of the picture is the edge of the outer well, which
was filled with medium containing MCP-1. The lower edge is the inner
well containing normal medium. Scale bar = 50 μm. (B) An example of
analysis of migrated distance represents vector diagrams of cell
displacement recorded one hour after setting up the Dunn chamber.
Each point represents the position of a cell, which at time 0 is positioned
at the intersection of the two axes. The × and Y axes are in μm. Labels:
FIB - indicates the coverglass was coated with fibronectin, MCP-1 -
monocyte chemoattractant protein-1, 300 - indicates 300 ng/ml
concentration of MCP-1.
Additional file 3: Stimulation of TG WT and TG G93A microglia with
1 mM ATP. (A) Intracellular calcium concentration ([Ca2+]i, μM) changes
in NTG (WT) and TG WT microglia following extracellular stimulation with
1 mM ATP for 1 min. The period of ATP challenge is indicated with the
bar. (B) Changes of [Ca2+]i in NTG (G93A) and TG G93A microglia
following extracellular stimulation with 1 mM ATP for 1 min. The period
of ATP challenge is indicated with the bar. (C) Area-under-the-curve
(AUC) values (μM*s) for NTG (WT), TG WT, NTG (G93A) and TG G93A
microglia. Data are mean ± SEM; Student’s t test, *p = 0.0201 versus NTG
(WT) microglia. (D) [Ca2+]i values (μM) recorded for NTG (WT), TG WT,
NTG (G93A) and TG G93A microglia at 130 s of recording (10 s after
initiation of 1 mM ATP challenge). Data are mean ± SEM; Student’s t test,
*p = 0.0381 versus NTG (WT) and **p = 0.0015 versus NTG (G93A) cells, n
= three NTG (WT) mice (14 cells) and three TG WT mice (18 cells) from
two litters, three NTG (G93A) mice (43 cells) and three TG G93A mice (38
cells) from two litters.
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